These results indicate that IGF-1R suppression enhances the potential of cisplatin therapy in phenotypically distinct breast cancer cell lines, and further indicates the benefit of combining IGF-1R inhibitors with DNA damaging agents. The gene discussed is IGF1R; the disease is breast cancer.